NX

Nexgel IncNASDAQ NXGL Stock Report

Last reporting period 30 Sep, 2024

Updated 25 Nov, 2024

Last price

Market cap $B

0.025

Micro

Exchange

XNAS - Nasdaq

NXGL Stock Analysis

NX

Uncovered

Nexgel Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-41/100

Low score

Market cap $B

0.025

Dividend yield

Shares outstanding

5.572 B

NexGel, Inc. engages in the manufacture of polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Langhorne, Pennsylvania and currently employs 10 full-time employees. The company went IPO on 2021-12-22. The firm is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The company is specialized in custom gels by capitalizing on proprietary manufacturing technologies. Its gels and its consumer products are manufactured using proprietary and non-proprietary mixing, coating and crosslinking technologies. Its hydrogels is marketed in the United States and abroad by its customers. The company markets under the brand names MedaGel and LumaGel Beauty. The products it sells under its MedaGel brand primarily relate to over-the-counter (OTC) remedy solutions, such as blister and pain applications; while the products it sells under its LumaGel Beauty brand primarily relate to beauty and cosmetic solutions, such as wrinkle and skin cream applications.

View Section: Eyestock Rating